Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 5/20 | 0.67 |
| ▸ | RXRA | P19793 | 4/20 | 0.67 |
| ▸ | RXRG | P48443 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11111979 | 0.98 | RXRB (0.64) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL30263704 | 0.93 | RXRA (0.57) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL20680969 | 0.93 | RXRA (0.57) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL7691902 | 0.90 | RXRB (0.56) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL9540541 | 0.89 | RXRB (0.56) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL27697415 | 0.88 | RXRB (0.55) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL7828378 | 0.88 | FFAR4 (0.56) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL21810616 | 0.87 | RXRB (0.53) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL7698029 | 0.86 | FFAR4 (0.55) | RXRBRXRARXRGALDH1A1ALOX15 | |
| SCHEMBL6348602 | 0.84 | RXRB (0.50) | RXRBRXRARXRGALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | UCB Biopharma SRL (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4081295-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2026-04-29 | — | — | EP | disclosed |
| EP-4081299-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2024-09-25 | — | — | EP | disclosed |
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2024-03-21 | — | — | US | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | disclosed |
| EP-4081295-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| CN-114980975-A | Dihydrocyclopentaisoquinoline sulfonamide derivatives | UCB生物制药有限责任公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| CN-1150183-C | New heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them | ɪά��ʵ���� | 2004-05-19 | — | — | CN | disclosed |
| CN-1492852-A | N-phenylpropylcyclopentyl substituted glutaramide derivatives as NEP inhibitors of FSAD | ������ҩ������˾ | 2004-04-28 | — | — | CN | disclosed |
| EP-1373192-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-6660756-B2 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002079143-A1 | N-PHENPROPYLCYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS NEP INHIBITORS FOR FSAD | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| US-5726208-A | Heterocyclic tertiary amines | ADIR ET COMPAGNIE (FR) | 1998-03-10 | — | — | US | disclosed |
| CN-1152572-A | New heterocyclic tertiary amines, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1997-06-25 | — | — | CN | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092773-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | FCER2, FCGR2A, FCGR1A | RXRB 1938/4885RXRA 2111/4885RXRG 1642/4885 |
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | HRH2, HRH4, HRH1 | RXRB 1876/4885RXRA 1878/4885RXRG 1650/4885 |
| US-20030105132-A1 | N-phenpropylcuclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | RXRB 3258/4885RXRA 3291/4885RXRG 3479/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | RXRB 974/4885RXRA 748/4885RXRG 971/4885 |
| US-20040106611-A1 | N-phenpropylcyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PREP, ENGASE, ENPEP | RXRB 2690/4885RXRA 2811/4885RXRG 2895/4885 |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | RXRB 1017/4885RXRA 1249/4885RXRG 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.